Author(s):
Lingaraj Anawal, Chandrashekar V M, Mallappa Shalavadi, Shubham Teli, Manjunath Madalageri, Veeresh Sadashivanavar, Vidya Patil, Sakkoobayi Kumbar, Prema Horatti
Email(s):
lingarajanawal@gmail.com
DOI:
10.52711/2231-5713.2024.00033 
Address:
Lingaraj Anawal*, Chandrashekar V M, Mallappa Shalavadi, Shubham Teli, Manjunath Madalageri, Veeresh Sadashivanavar, Vidya Patil, Sakkoobayi Kumbar, Prema Horatti
Department of Pharmacology, BVVS Hanagal Shri Kumareshwar College of Pharmacy, Bagalkote, Karnataka India.
*Corresponding Author
Published In:
Volume - 14,
Issue - 3,
Year - 2024
ABSTRACT:
Objective: The current study was designed to study the neuroprotective effect of Polyherbal formulation against the Colchicine-induced Alzheimer’s disease rat model. Methods: The memory enhancing activity of Polyherbal formulation was demonstrated by the intracerebroventricular administration of colchicine in Sprague-dawley rats. The effect of Polyherbal formulation were studied by evaluating the neurobehavioral assessment parameters like Morris water maze test, Locomotor activity, Open filed and Elevated plus maze test were performed at 0, 7, 14 and 28 days for assessing the cognitive and gross behavioral activities in all groups. Results and Discussion: The effect of Polyherbal formulation shows a neuroprotective activity with significant (p<0.001) decrease in Mean transfer latency, Time spent in open arm, Number of entries in open arm, escape latency, number of ambulatory movement, latency, numbering of rearing, number of grooming, rest and significant (p<0.001) increase in time spent closed arm, number of entries in closed arm, Probe trail, time spent in platform quadrant and spontaneous locomotion, number of ipsilateral rotation. Conclusion: In conclusion, the result of current study evidenced that the Polyherbal formulation (PHF) showed potent neuroprotective activity against colchicine induced Alzheimer’s disease.
Cite this article:
Lingaraj Anawal, Chandrashekar V M, Mallappa Shalavadi, Shubham Teli, Manjunath Madalageri, Veeresh Sadashivanavar, Vidya Patil, Sakkoobayi Kumbar, Prema Horatti. Neuroprotective Activity of Polyherbal Formulation on Colchicine Induced Alzheimer’s Disease in Rat Model. Asian Journal of Pharmacy and Technology. 2024; 14(3):199-7. doi: 10.52711/2231-5713.2024.00033
Cite(Electronic):
Lingaraj Anawal, Chandrashekar V M, Mallappa Shalavadi, Shubham Teli, Manjunath Madalageri, Veeresh Sadashivanavar, Vidya Patil, Sakkoobayi Kumbar, Prema Horatti. Neuroprotective Activity of Polyherbal Formulation on Colchicine Induced Alzheimer’s Disease in Rat Model. Asian Journal of Pharmacy and Technology. 2024; 14(3):199-7. doi: 10.52711/2231-5713.2024.00033 Available on: https://ajptonline.com/AbstractView.aspx?PID=2024-14-3-2
REFERENCES:
1. Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid ß deposition, neurodegeneration and cognitive decline in sporadic Alzheimer’s disease: A prospective cohort study. The Lancet Neurology. 2013; 12(4):357-67. https://doi.org/10.1016/s1474-4422(13)70044-9
2. Reiman EM, Quiroz YT, Fleisher AS, Chen K, Velez-Pardos C, JimenezDel-Rio M, et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer’s disease in the presenilin 1 E280A kindred: A case-control study. The Lancet Neurology. 2012; 11(2):1048-56. https://doi.org/10.1016/s1474-4422(12)70228-4
3. Jack CR, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, et al. Serial PiB and MRI in normal, mild cognitive impairment and Alzheimer’s disease: Implications for sequence of pathological events in Alzheimer’s disease. Brain. 2009; 132:1355- 65. https://doi.org/10.1093%2Fbrain%2Fawp062
4. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. The New England Journal of Medicine. 2012; 367(9):795-804. https://doi.org/10.1056/nejmoa1202753
5. Gordon BA, Blazey TM, Su Y, Hari-Raj A, Dincer A, Flores S, et al. Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer’s disease: A longitudinal study. The Lancet Neurology. 2018; 17(3):241-50. https://doi.org/10.1016/s1474-4422(18)30028-0
6. Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. Journal of Neuropathology and Experimental Neurology. 2011; 70(11):960-9. https://doi.org/10.1097/nen.0b013e318232a379
7. Sato C, Barthélemy NR, Mawuenyega KG, Patterson BW, Gordon BA, Jockel-Balsarotti J, et al. Tau kinetics in neurons and the human central nervous system. Neuron. 2018; 98(4):861. https://doi.org/10.1016/j.neuron.2018.02.015
8. Hanseeuw BJ, Betensky RA, Jacobs HIL, Schultz AP, Sepulcre J, Becker JA, et al. Association of amyloid and tau with cognition in preclinical Alzheimer disease. JAMA Neurology. 2019; 76(8):915-24. https://doi.org/10.1001/jamaneurol.2019.1424
9. Desai S, Hugar S, Nanjappaiah HM, Patil VP. Effect of Sumanas, a polyherbal formulation, on learning and memory in animal models of Alzheimer’s disease. BLDE University Journal of Health Sciences. 2020: 1;5(3):34. http://dx.doi.org/10.4103/2468-838X.303781
10. Sane RT. Standardization, quality control and GMP for herbal drug. Indian drugs 2002; 39(3):184-190.
11. Farnsworth NR, Akerele O, Bingle AS, Sojarto DD, Guo Z. Medicinal plant in therapy. Bulletin of the world health organization.1985;63:965-981. https://pubmed.ncbi.nlm.nih.gov/ 3879679
12. Abraham R, Paridhavi M. A review of comprehensive study on medicinal plants of polyherbal formulation- Churna. Asian Journal of Pharmaceutical and Clinical Research. 2013; 6(4):11-18.
13. Kunwar RM, Shrestha KP. Bussmann RW. Traditional herbal medicine in far west Nepal: a pharmacological appraisal. Journal of Ethnobiology and Ethnomedicine. 2010; 6: 35. https://doi.org/10.1186/1746-4269-6-35
14. Ngo LT, Okogan J, Folk WR 21 century natural product research and drug development and traditional medicines. Natural Products reports. 2014; 30(4):584-92. https://doi.org/10.1039/c3np20120a
15. Che CT, Wang ZJ, Chow MSS, Lam CWK. Herb-herb combination for therapeutic enhancement and advancement: Theory, practice and future perspectives. Molecules. 2013;18(5):5125-41. https://doi.org/10.3390/molecules18055125
16. Risberg K. Fodstad Q, Andersson Y. Synergistic anticancer effects of the 9.2.27PE immunatoxin and ART-737 in melanoma. PloS One. 6 (9)e24012. https://doi.org/10.1371/journal.pone.0024012
17. Ramaiah M, Chadravathi G, Yasaswini K. In vitro biological standardization formulation and evaluation of directly compressed polyherbal anthelmintic tablets. Pharmacognosy Journal. 2013; 5(3):130-4. http://dx.doi.org/10.1016/j.phcgj.2013.04.004
18. Ajazuddin, Saraf S. Evaluation of physicochemical and phytochemical properties of Safoof-E-Sana, a Unani polyherbal formulation. Pharmacognosy Research. 2010; 25: 318-22. https://doi.org/10.4103/0974-8490.72332
19. Lu N, Li Y, Qin H, Zhang Y. Sun C. Gossypin up-regulates LDL receptor through activation of ERK pathway a signaling mechanism for the hypocholesterolemic effect. Journal of Agricultural and Food Chemistry. 2008; 56:11526-11532. https://doi.org/10.1021/jf802607x
20. Ramaswamy S, Vishwanathan.S. "Influence of Gossypin on the development of acutetolerance to morphine induces antinociception, Indian Journal of Experimental Biology. 1997; 35:413-414.
21. Gujjula N, Gurram AL, Lagadapati T, Amrutha M, Kuruva R, Nikitha KR. Bobillapati J. Naga SK. Rahamat U. In vitro cytotoxic activity of ethyl acetate fraction of Hibiscus vitifolius flowers against Hela Cell Line. Tropical Journal of Natural Products Research. 2018; 11:122. http://www.doi.org/10.26538/tjnpr/v1i4.5
22. Anbu Jeba SJS, Syam M, Dinesh KC, Anandarajagopal K. Saraswathi A. "Hibiscus vitifolius L root extracts shows potent protective action against anti-tubercular drug induced hepatotoxicity." Journal of Ethnopharmacology. 2012; 141:396-402. https://doi.org/10.1016/j.jep.2012.02.051
23. Neeraj KS, Mishra SH. Review on ethnomedicinal uses and phytopharmacology of memory boosting herb Convolvulus pluricaulis Choisy. Australian Journal of Medicinal Herb. 2010; 22(1):19-26.
24. Dinesh D. Rekha V. Evaluation of the antidepressant-like activity of Convolvulus pluricaulis choisy in the mouse forced swim and tail suspension tests. Medical Science Monitor. 2007;13(7):155-161.
25. Theodore C. Flora of Presidency of Mumbay, Taylor and Francis, London 1908:2:233.
26. Basu NK, Dandiya PC. Chemical investigation of Convolvulus pluricaulis. Journal of the Amercian Pharmaceutical Association. 1948: 37:27-8. https://pubmed.ncbi.nlm.nih.gov/18899765/
27. Prasad GC, Gupta RC, Srivastava DN, Tandon AD, Wahi R, Udupa KN. Effect of Shankhpushpi on experimental stress. Journal of Research Indian Medicine. 1974, 9(2):19-27.
28. Lounasmaa M. Tropane Alkaloids in The Alkaloids, Chemistry and Pharmacology. Arnold Brossi. New York: Academic Press 1988.
29. Singh GK. Bhandari. Text book of Pharmacognosy 1st edn. New Delhi: CBS Publishers 2000.
30. Chunekar KC. Bhavaprakasanighantu of Sri Bhavamisra Commentary Varanasi. 1982; 455.
31. Sharma PV. Dravyaguna vijnana Varanasi. 1983;10-11.
32. Adams M, Gmunder F, Hamburger M. Plants traditionally used in age related brain disorders: a survey of ethnobotanical literature. Journal of Ethnopharmacology. 2007; 113: 363-81. https://doi.org/10.1016/j.jep.2007.07.016
33. Bala VM. Dementia in Ayurveda. Journal of Alternative Complementary Medicine. 1999: 5: 81-8. https://doi.org/10.1089/acm.1999.5.81
34. Dhingra D. Valecha R. Screening for antidepressant-like activity of Convolvulus pluricaulis Choisy in mice. Pharmacology online. 2007; 1: 262-278.
35. Hsing-TL, Hui-M, Wu HC, Chi-Ming Liu and Chung-Yi Chen. The Pharmacological Activities of (-) Anonine. Molecules. 2013; 18: 8257-8263. https://doi.org/10.3390/molecules18078257
36. Yeh YT, Huang JC, Kuo PL, Chen CY. Bioactive constituents from Michelia champaca. Naturatl Products Communcation. 2011; 6(9): 1251-2.
37. Lisa. offering Medicinal plants of northern Thailand for the treatment of cognitive impairment in the elderly. Springer International Publishing Switzerland. 2015:61-62.
38. Warrier PK. Nambiar VP. Ramankutty C. Indian Medicinal Plants-A Compendium of 500 Species. 1st ed. India: Orient Longman Publishers; 1994. p. 4-6.
39. Shukla D, Srivastava S, Jawaid T. Learning and Memory Enhancing Activity of Polyherbal Formulation on Streptozotocin Induced Memory Impairment in Rats via Reducing Mitochondria–Targeted Cytochrome. Pharmacognosy Journal. 2021; 13(1): 230-40. http://dx.doi.org/10.5530/pj.2021.13.33
40. OECD Guidelines for Testing of Chemicals 425. Acute Oral Toxicity - Acute toxic class method, 2001.
41. John, J.; Sapa, N.K.; Shenoy, R.R. Virgin coconut oil ameliorates colchicine induced cognitive dysfunction - a preclinical study. Ulum-i Daruyi, 2020, 26(1),1-12. https://doi.org/10.34172/PS.2019.61
42. Lingaraj Anawal, Chandrashekar Venkaraddi Mangannavar, Mallappa Shalavadi and Shubham Teli. The Natural Products Journal. 2023; 13 (8): 1-15. https://dx.doi.org/10.2174/2210315513666230316100124
43. Veerendra Kumar MH, Gupta YK. Intracerebroventricular administration of colchicine produces cognitive impairment associated with oxidative stress in rats. Pharmacology Biochemistry and Behavior. 2002; 73(3): 565-571. https://doi.org/10.1016/s0091-3057(02)00838-9
44. Kumar, A.; Dogra, S.; Prakash, A. Protective effect of naringin, a citrus flavonoid, against colchicine-induced cognitive dysfunction and oxidative damage in rats. Journal of Medicinal Food. 2010, 13(4), 976-984. https://doi.org/10.1089/jmf.2009.1251
45. Mohamed, A.R.; Soliman, G.Y.; Ismail, C.A.; Mannaa, H.F. Neuroprotective role of vitamin D3 in colchicine-induced Alzheimer’s disease in rats. Alexandria Journal of Medicine. 2015; 51(2): 127-136. https://doi.org/10.1016/j.ajme.2014.05.005
46. Zhao, Y.; Dang, M.; Zhang, W.; Lei, Y.; Ramesh, T.; Priya Veeraraghavan, V.; Hou, X. Neuroprotective effects of syringic ac- id against aluminium chloride induced oxidative stress mediated neuroinflammation in rat model of Alzheimer’s disease. Journal of Functional Foods. 2020; 71.104009. https://doi.org/10.1016/j.jff.2020.104009
47. Adham R. Mohamed, Gehan Y. Soliman, Cherine A. Ismail & Hazem F. Mannaa. Neuroprotective role of vitamin D3 in colchicine-induced Alzheimer’s disease in rats. Alexandria Journal of Medicine. 2015; 51(2): 127-136, https://doi.org/10.1016/j.ajme.2014.05.005
48. Firuzi O, Pratic OD. Coxib and Alzheimer’s disease: should they stay or should they go?. Ann Neurol. 2006; 59(2): 219-28.
49. Mcllroy S, Craig D. Neurobiology and genetics of behavioral syndromes of Alzheimer’s disease. Current Alzheimer’s Research. 2004; 1:135-42. https://doi.org/10.2174/1567205043332180
50. Vina J. Lloret A, Ort IR, Alonso D. Molecular basis of the treatment of Alzheimer’s disease with antioxidants: prevention of oxidative stress. Molecular Aspects of Medicine. 2004; 25(1-2):117-23. https://doi.org/10.1016/j.mam. 2004.02.013
51. Kumar A, Naidu PS, Segal N, Padi SSV, Goyl R. Colchicine induced neurotoxicity as a animal model of sporadic dementia of Alzheimer’s type. Pharmacology Reports. 2007; 59(3):274-83.
52. Spillantini MG, Goedert M. Tau protein pathology in neurodegenerative diseases. Trends in Neuroscience.1998; 21(10):428-33. https://doi.org/10.1016/s0166-2236(98)01337-x
53. Mandelkow EM, Stamer K, Vogel R, Thies E, Mandelkov E. Clogging of axons by tau, inhibition of axonal traffic and starvation of synopses. Neurobiology of Ageing. 2003; 24(8): 1079-85. https://doi.org/10.1016/j.neurobiolaging.2003.04.007
54. Paris D, Parker TA, Town T, Suo ZM, Fang CH, Humphery J et al. Role of peroxynitrite in the vasoactive and cytotoxic effects of Alzeimer’s β-Amyloid peptide. Experimental Neurology. 1998; 152: 116-22. https://doi.org/10.1006/exnr.1998.6828